Handelsbanken Fonder’s Summit Therapeutics SMMT Stock Holding History

Handelsbanken Fonder’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$809K	Buy	55,500 +10,900	+24%	+$193K	﹤0.01%	1224
2026 Q1	$846K	Buy	44,600 +7,000	+19%	+$113K	﹤0.01%	1109
2025 Q4	$658K	Buy	37,600 +3,400	+10%	+$64K	﹤0.01%	1211
2025 Q3	$707K	Hold	34,200	–	–	﹤0.01%	1151
2025 Q2	$728K	Sell	34,200 -2,900	-8%	-$66.1K	﹤0.01%	1087
2025 Q1	$716K	Hold	37,100	–	–	﹤0.01%	1087
2024 Q4	$662K	Sell	37,100 -50,900	-58%	-$987K	﹤0.01%	1177
2024 Q3	$1.93M	Buy	88,000 +24,100	+38%	+$337K	0.01%	677
2024 Q2	$498K	Buy	+63,900	New	+$345K	﹤0.01%	1160

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Handelsbanken Fonder's SMMT Position: Q2 2026 in Review

Handelsbanken Fonder increased its Summit Therapeutics (SMMT) stake by 24% in Q2 2026, buying an estimated $193K and bringing the position to 55,500 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

Handelsbanken Fonder first reported a position in SMMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.93M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Handelsbanken Fonder held 55,500 shares of Summit Therapeutics worth $809K as of Q2 2026.
Handelsbanken Fonder bought 10,900 Summit Therapeutics shares in Q2 2026, an estimated $193K.
Summit Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1224 holding.
Handelsbanken Fonder first reported a position in Summit Therapeutics in Q2 2024 and has held it in 9 quarters since.
Handelsbanken Fonder's Summit Therapeutics position peaked at $1.93M in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.